NYSE:CTLT - Catalent Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $142.86
  • Forecasted Upside: 34.78 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1.03 (-0.96%)

This chart shows the closing price for CTLT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Catalent Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTLT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTLT

Analyst Price Target is $142.86
▲ +34.78% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Catalent in the last 3 months. The average price target is $142.86, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 34.78% upside from the last price of $105.99.

This chart shows the closing price for CTLT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Catalent. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2022Deutsche Bank AktiengesellschaftLower Price TargetHold$129.00 ➝ $110.00High
2/2/2022Morgan StanleyLower Price TargetOverweight$160.00 ➝ $145.00Low
1/27/2022BarclaysLower Price TargetOverweight$160.00 ➝ $130.00Low
12/16/2021BarclaysInitiated CoverageOverweight$160.00Low
11/3/2021Morgan StanleyBoost Price TargetOverweight$147.00 ➝ $160.00Low
11/3/2021Royal Bank of CanadaBoost Price TargetOutperform$145.00 ➝ $155.00Low
9/8/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$123.00 ➝ $162.00Medium
8/31/2021UBS GroupBoost Price TargetBuy$138.00 ➝ $145.00Low
8/31/2021KeyCorpBoost Price TargetOverweight$142.00 ➝ $155.00Low
8/31/2021Bank of AmericaBoost Price TargetBuy$140.00 ➝ $160.00Low
8/31/2021Morgan StanleyBoost Price TargetOverweight$135.00 ➝ $147.00Low
8/31/2021Royal Bank of CanadaBoost Price TargetOutperform$137.00 ➝ $145.00Low
3/2/2021ArgusBoost Price TargetBuy$130.00 ➝ $140.00Medium
2/3/2021Morgan StanleyBoost Price TargetOverweight$115.00 ➝ $135.00High
2/3/2021UBS GroupBoost Price TargetBuy$115.00 ➝ $135.00High
2/3/2021Royal Bank of CanadaBoost Price TargetOutperform$125.00 ➝ $137.00High
1/8/2021JPMorgan Chase & Co.Boost Price TargetOverweight$110.00 ➝ $130.00Low
11/5/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$91.00 ➝ $100.00Low
11/4/2020Robert W. BairdBoost Price TargetOutperform$100.00 ➝ $109.00High
11/4/2020Jefferies Financial GroupBoost Price TargetBuy$107.00 ➝ $115.00High
11/4/2020UBS GroupBoost Price TargetBuy$105.00 ➝ $115.00High
11/4/2020Royal Bank of CanadaBoost Price TargetOutperform$98.00 ➝ $105.00High
11/4/2020Morgan StanleyBoost Price TargetOverweight$98.00 ➝ $115.00High
9/24/2020ArgusBoost Price Target$100.00 ➝ $110.00Low
9/4/2020Deutsche Bank AktiengesellschaftBoost Price TargetIn-Line ➝ Hold$62.00 ➝ $91.00Low
9/1/2020Royal Bank of CanadaBoost Price Target$94.00 ➝ $98.00Low
9/1/2020Morgan StanleyBoost Price TargetOverweight$95.00 ➝ $98.00High
9/1/2020Robert W. BairdBoost Price TargetPositive ➝ Outperform$90.00 ➝ $100.00High
8/11/2020Jefferies Financial GroupReiterated RatingBuy$105.00High
7/31/2020Morgan StanleyBoost Price TargetOverweight$75.00 ➝ $95.00Low
7/21/2020UBS GroupBoost Price TargetBuy$77.00 ➝ $97.00Low
7/14/2020Royal Bank of CanadaBoost Price TargetPositive ➝ Outperform$78.00 ➝ $86.00Medium
6/26/2020Robert W. BairdBoost Price TargetOutperform$74.00 ➝ $80.00Medium
6/25/2020ArgusInitiated CoverageBuyMedium
5/6/2020Robert W. BairdBoost Price TargetOutperform$63.00 ➝ $74.00Low
5/6/2020Morgan StanleyBoost Price TargetOverweight$57.00 ➝ $75.00Low
5/6/2020UBS GroupBoost Price TargetBuy$70.00 ➝ $77.00Low
5/6/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$59.00 ➝ $62.00High
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$65.00High
4/13/2020Robert W. BairdLower Price TargetOutperform$67.00 ➝ $63.00Low
3/27/2020Morgan StanleyLower Price TargetOverweight$67.00 ➝ $57.00High
3/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$59.00High
2/4/2020Robert W. BairdReiterated RatingOutperform$60.00 ➝ $67.00High
2/4/2020Morgan StanleyBoost Price TargetOverweight$64.00 ➝ $67.00Medium
1/27/2020StephensBoost Price TargetOverweight$65.00 ➝ $75.00Low
10/17/2019StephensInitiated CoverageOverweight$56.00High
8/28/2019Robert W. BairdBoost Price TargetOutperform$50.00 ➝ $60.00Low
8/28/2019Morgan StanleyBoost Price TargetOverweight$50.00 ➝ $61.00Low
7/23/2019UBS GroupBoost Price TargetBuy$64.00Low
6/21/2019Jefferies Financial GroupUpgradeHold ➝ Buy$50.00 ➝ $62.00High
4/16/2019Morgan StanleyBoost Price TargetOverweight$46.00 ➝ $50.00High
4/16/2019Jefferies Financial GroupBoost Price TargetHold$44.00 ➝ $50.00High
4/16/2019UBS GroupUpgradeNeutral ➝ Buy$43.00 ➝ $54.00High
3/5/2019First AnalysisReiterated RatingOutperform$49.00Low
12/3/2018Morgan StanleySet Price TargetBuy$46.00Low
11/16/2018Royal Bank of CanadaSet Price TargetBuy$45.00Low
11/15/2018Robert W. BairdInitiated CoverageOutperformLow
11/7/2018Royal Bank of CanadaSet Price TargetBuy$44.00Medium
11/7/2018First AnalysisUpgradeNeutral ➝ Outperform$47.00 ➝ $43.00High
10/9/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$48.00Low
8/29/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$50.00 ➝ $55.00Medium
3/28/2018KeyCorpUpgradeSector Weight ➝ Overweight$48.00Medium
3/21/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$48.00High
3/21/2018UBS GroupUpgradeMarket Perform ➝ OutperformHigh
2/6/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$47.00 ➝ $49.00Medium
2/6/2018StephensDowngradeOverweight ➝ Equal WeightHigh
2/5/2018Royal Bank of CanadaSet Price TargetBuy$48.00High
1/24/2018The Goldman Sachs GroupInitiated CoverageBuy$50.00High
1/5/2018First AnalysisInitiated CoverageEqual WeightLow
12/13/2017Royal Bank of CanadaInitiated CoverageOutperform$46.00Low
11/7/2017Piper Jaffray CompaniesBoost Price TargetOverweight$45.00 ➝ $50.00N/A
10/23/2017Needham & Company LLCReiterated RatingHoldN/A
9/21/2017Morgan StanleyUpgradeEqual Weight ➝ Overweight$29.00 ➝ $48.00High
9/20/2017Bank of AmericaReiterated RatingBuy$40.00 ➝ $45.00Low
9/20/2017Wells Fargo & CompanyBoost Price TargetOutperform$39.00 ➝ $43.00Low
9/12/2017Needham & Company LLCInitiated CoverageHold$42.00Low
8/31/2017Wells Fargo & CompanyReiterated RatingOutperform$30.00 ➝ $39.00Medium
8/29/2017Bank of AmericaReiterated RatingBuy$38.00 ➝ $40.00Medium
8/29/2017William BlairReiterated RatingOurperformHigh
8/29/2017Jefferies Financial GroupReiterated RatingHold$35.00 ➝ $38.00High
8/29/2017JPMorgan Chase & Co.Reiterated RatingBuy$40.00High
8/29/2017Piper Jaffray CompaniesReiterated RatingBuy$45.00High
7/21/2017Bank of AmericaReiterated RatingBuy$37.00 ➝ $38.00Low
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 26 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 32 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 9 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Catalent logo
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Read More

Today's Range

Now: $105.99
Low: $102.58
High: $106.13

50 Day Range

MA: $102.31
Low: $88.26
High: $113.71

52 Week Range

Now: $105.99
Low: $86.34
High: $142.64


856,806 shs

Average Volume

1,240,430 shs

Market Capitalization

$18.99 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Catalent?

The following Wall Street analysts have issued reports on Catalent in the last year: Bank of America Co., Barclays PLC, Deutsche Bank Aktiengesellschaft, KeyCorp, Morgan Stanley, Royal Bank of Canada, StockNews.com, and UBS Group AG.
View the latest analyst ratings for CTLT.

What is the current price target for Catalent?

0 Wall Street analysts have set twelve-month price targets for Catalent in the last year. Their average twelve-month price target is $142.86, suggesting a possible upside of 34.8%.
View the latest price targets for CTLT.

What is the current consensus analyst rating for Catalent?

Catalent currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CTLT will outperform the market and that investors should add to their positions of Catalent.
View the latest ratings for CTLT.

How do I contact Catalent's investor relations team?

Catalent's physical mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company's listed phone number is (732) 537-6200 and its investor relations email address is [email protected] The official website for Catalent is www.catalent.com. Learn More about contacing Catalent investor relations.